Skip Ribbon Commands
Skip to main content

Scientific Agenda

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   /   Meetings   /   BMT Tandem Meetings   /   Scientific Agenda
  • Print
  • Share

 BMT Tandem Meetings Scientific Agenda


7:15 am-8:15 am – BMT Tandem Meetings Symposium 

8:15 am-8:30 am – Break

8:30 am-10:00 am – Opening Plenary Session  
Viral Infections

Per Ljungman, MD, PhD, Chair
   Epidemiology and Clinical Aspects of Community Acquired Respiratory
   Virus Infections
         Janet Englund, MD
   Adoptive Therapy with Adenovirus-Specific T Cells
         Tobias Feuchtinger, MD
   Vaccination of Stem Cell Transplant Recipients Against Viral Pathogens
        Per Ljungman, MD, PhD

10:00 am-10:30 am – Break

10:30am-12:00 pm
Cutting Edge Issues in Innate Immunity
Douglas Golenbock, MD, Chair
  The NLRP3 Inflammasone: Mediator of INflammatory Illnesses
         Luke O'Neill, PhD
   DNA Receptors in Inflammatory Disorders and Infectious Diseases
         Douglas Golenbock, MD
   SNP's of NOD-Like and Tell-Like Receptors - Functional Consequences
        Ernst Holler, MD

Myelodysplastic Syndrome (MDS)
Richard Champlin, MD, Chair
   Pathophysiology of MDS
          Stephen Nimer, MD
   Treatment of MDS
          Guilermo Garcia-Manero, MD
   Stem Cell Transplantation for MDS
         Richard Champlin, MD

Ethical Issues in Hematopoietic Cellular Therapies Research
Steven Joffe, MD, MPH, Chair
   The Ethical Involvement of Donors in HCT Clinical Research
          Michael Pulsipher, MD
   Conflicts of Interest: Genuine Tempest or Much Ado About Nothing?
          Bernard Lo, MD
   Conflict of Interest in Clinical Research
          Steven Joffe, MD, MPH

12:30 pm-1:30 pmBMT Tandem Meetings Symposium

4:45 pm-6:45 pm
Oral Abstracts

6:45 pm
Poster Session I and Welcome Reception


7:15 am-8:15 am – BMT Tandem Meetings Symposium

8:15 am-8:30 am – Break 

8:30 am-10:00 am
Genetically Modified T Cells
Helen Heslop, MD, Chair
   Genetic Modification of T Cells with Anti-tumor Antigen TCR Genes
         Mark Dudley, PhD
   Modifying T Lymphocytes to Express Chimeric Antigen Receptors and to Overcome Tumor Immune Evasion 
         Malcolm Brenner, MD, PhD
   Moving the Suicide Gene Strategy to Phase 3 Trials Post-Transplant
         Chiara Bonini, MD

10:00 am-10:30 am – Break


10:30 am-12:00 pm
MSCs in Hematopoietic Cell Transplantation (ISCT Session)

Edwin M. Horwitz, MD, PhD, Chair
   The Many Faces of MSCs
         Edwin M. Horwitz, MD, PhD
   MSCs to Promote HSC Engraftment
         Richard Maziarz, MD
   MSCs in the Treatment of Acute and Chronic Graft versus Host Disease
         Partow Kebriaei, MD

Myeloma Debate

Sergio Giralt, MD, Chair
   Role of Allogeneic HCT in Myeloma: Data from BMT CTN 0102
         Edward Stadtmauer, MD
   Role of Maintenance Therapy after Autologous HCT: Data from CALGB 100104
         Philip McCarthy, MD
   Early versus Late Autografting: Results from the GITMO
         Antonio Palumbo, MD

Graft versus Leukemia (GVL)
JH Frederik Falkenburg, MD, Chair
   Preclinical Studies on GVL Reactivity
        Warren D. Shlomchik, MD
   GVL Responses by CDT T Cells
        Edus H. Warren, MD
   GVL Responses by CDT T Cells
       JH Frederik Falkenburg, MD
12:30 pm-1:30 pm – BMT Tandem Meetings Symposium
4:45 pm-6:45 pm
Oral Abstracts


6:45 pm-7:15 pm
CIBMTR General Assembly 

7:15 pm-8:00 pm
Mortimer M. Bortin Lecture 


7:15 am-8:15 am – BMT Tandem Meetings Symposium

8:15 am-8:30 am – Break

8:30 am-10:00 am
Novel Cord Blood Transplant Therapies
Elizabeth J. Shpall, MD, Chair
   Improved Cord Blood Engraftment with Ex Vivo Expansion and Fucosylation
         Elizabeth J. Shpall, MD
   Virus and Tumor-Specific Cord Blood Immune Cells
         Catherine Bollard, MD, PhD
   Cord Blood-Derived Regulatory T Cells
         Claudio Brunstein MD

10:00 am-10:30 am – Break

10:30 am-12:00 pm
Cord Blood Unit Access and Selection (NMDP Session)
Dennis Confer, MD, Chair
   Implications of Cord Blood Licensure for Transplant Programs
         Michael Boo, MD
   Applying Cord Blood Match Rates to Search Algorithms
         Martin Maiers, PhD
   Best Practices and Emerging Trends in Cord Blood Unit Selection
         Karen Ballen, MD

Genomics as a Tool for Discovery
Stella Davies, MD, PhD, Chair
   Genomic Studies in AML
         John DiPersio, MD
   Genomic Approaches to HLA
         Effie Petersdorf, MD
   Genomic Approaches to ALL
         Charles Mullighan, MD
Acute GVHD
Warren D. Shlomchik, MD, Chair
Immune Regulation of Graft versus Host Disease
         Bruce Blazar, MD

  Antigen Presentation and GVHD: Where and When?
         Geoff Hill, MD
   All GVHD is Local: The Primacy of Intestinal GVHD
         Marcel R.M. van den Brink, MD

12:30 pm-1:30 pm – BMT Tandem Meetings Symposium
4:45 pm-6:15 pm
Best Abstracts Session
6:15 pm-6:30 pm
ASBMT Business Meeting

6:30 pm-7:15 pm
E. Donnall Thomas Lecture




7:15 am-8:15 am – BMT Tandem Meetings Symposium

8:15 am-8:30 am – Break

8:30 am-10:00 am
Induced Pluripotent Stem Cells
George Q. Daley, MD, Chair
   Patient-specific Reprogrammed Stem Cells for Combining Gene Repair and Cell Therapy
         George Q. Daley, MD
   Tracing the Origins of Hematopoietic Stem Cells
         Shin-ichi Nishikawa, MD
   Reprogramming of Fanconi Anemia and Other Human Diseases
         Juan-Carlos Izpisua-Belmonte, MD
10:00 am-10:30 am – Break

10:30 am-12:00 pm
T-Regulatory Cells

Robert Negrin, MD, Chair
   Biology of Regulatory T Cells
         Shirim Sakaguchi, MD
   Regulatory T Cells and Graft versus Host Disease
         Jerome Ritz, MD
   Regulatory T Cells in Allogeneic HCT from Mouse to Man
         Robert Negrin, MD

WBMT Session
Dennis Confer, MD, Yoshihisa Kodera, MD and Dietger Niederwieser, MD, Co-Chairs
   Update on WBMT activity
            Dietger Niederwieser, MD
Activity Survey data 2007-2008
           Helen Baldomero, MD
Reporting on APBMT Congress Meeting/HCT Activity/VietNam meeting
          Yoshihisa Kodera, MD
Harmonizing Standards in BMT – Improving Outcomes on a Global Scale
           Kathy Loper, MD
WHO and WBMT a model for optimal collaboration between scientists and Health

          Luc Noel, MD

Reduced Intensity Transplants for CLL and Indolent Lymphoma
John Gribben, MD, DSc, Chair
   Challenges of RICs for Indolent Lymphomas and CLL
            David Maloney, MD, PhD
   Mechanisms of Escape of CLL and Lymphoma Cells from Immune Recognition
           John Gribben, MD, DSc
  Methods to Expand Autologous, Allogeneic and Cord Blood T Cells to Augment 
   the GVL Effect in CLL and Lymphoma
          Chitra Hosing, MD

12:30 pm-1:30 pm – BMT Tandem Meetings Symposium

1:30 pm-3:00 pm
BMT Medical Directors Conference

4:45 pm-6:45 pm
Oral Abstracts
6:45 pm-7:45 pm
Poster Session II

8:00 pm-11:00 pm
ASBMT President's Gala


7:00 am-8:00 am – Continental Breakfast
8:00 am-9:30 am
Acute Lymphoblastic Leukemia

Anthony Goldstone, MD, Chair
   Who Gets a Transplant in PH Negative Adult ALL
            Anthony Goldstone, MD
   Adult ALL - Is Transplant Still Necessary?
           Adele Fielding, MD, PhD
   Interpreting Data on Transplant Selection and Outcome in Adult ALL
          Jacob Rowe, MD

9:30 am-10:00 am – Break

10:00 am-11:30 am
Oral Abstracts
11:30 am-12:00 pm – Luncheon Break

12:00 pm -1:30 pm
Point - Counterpoint: Cord Blood or Haploidentical Donor?
A. John Barrett, MD and Alejandro Madrigal, MD, PhD, Co-Chairs
Cord Blood Transplants
           Eliane Gluckman, MD
Haploidentical Transplants
          Rupert Handgretinger, MD

Minimal Residual Disease (MRD) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Michael R. Bishop, MD, Chair
Summary of the NCI 1st International Workshop on the Biology, Prevention and 
   Treatment of Relapse after HCT
          Michael R. Bishop, MD
Monitoring MRD after HCT
          Nicolaus Kroger, MD
Treatment Options for MRD after HCT:  Adoptive Immunotherapy and Beyond
          Koichi Miyamura, MD
1:30 pm
BMT Tandem Meetings Adjourn

(More details will be posted to this page as they become available.)

Last Updated: 5/18/2015 6:21 PM